International Journal of Surgical Research
International Journal of Surgical Research. 2021; 4: (1) ; 10.12208/j. ijsr.20210010 .
总浏览量: 961
江苏省响水县人民医院 江苏盐城
*通讯作者: 董明,单位:江苏省响水县人民医院 江苏盐城;
目的 分析高龄急性脑梗死静脉溶栓治疗的有效性和安全性。方法 本文一共纳入50例实验对象,均是2020年6月至2021年11月来我院诊治的高龄急性脑梗死患者,利用红绿双色球法进行分组,分为对照组(n=25,常规治疗)与研究组(n=25,静脉溶栓治疗)。对比分析两组的神经功能、日常生活能力以及血管内皮功能,统计两组的并发症。结果 在NIHSS评分与BI评分上,研究组优于对照组(P<0.05)。在血浆内皮素-1(ET-1)与一氧化氮(NO)上,研究组优于对照组(P<0.05)。在并发症发生率上,两组差异不大(P>0.05)。结论 静脉溶栓治疗高龄急性脑梗死患者的效果良好,临床可进一步推广运用。
Objective to analyze the efficacy and safety of intravenous thrombolysis in elderly patients with acute cerebral infarction. Methods a total of 50 experimental subjects were included in this paper. They were all elderly patients with acute cerebral infarction treated in our hospital from June 2020 to November 2021. They were divided into control group (n = 25, routine treatment) and study group (n = 25, intravenous thrombolytic treatment) by red and green double color ball method. The neurological function, activities of daily living and vascular endothelial function of the two groups were compared and analyzed, and the complications of the two groups were counted. Results in NIHSS score and Bi score, the study group was better than the control group (P < 0.05). In plasma endothelin-1 (ET-1) and nitric oxide (no), the study group was better than the control group (P < 0.05). There was no significant difference in the incidence of complications between the two groups (P > 0.05). Conclusion intravenous thrombolysis is effective in the treatment of elderly patients with acute cerebral infarction, which can be further popularized in clinic.
[1] 马灿灿,张熙斌,李晓波,等.高龄急性脑梗死患者阿替普酶静脉溶栓有效性、安全性及预后影响因素分析[J].中国卒中杂志,2020,15(9):972-977.
[2] 葛建亮,刘晓微,曹红玉,等.高龄脑梗死急性期患者静脉溶栓的有效性及安全性分析[J].中华老年心脑血管病杂志,2020,22(11):1189-1192.
[3] 张勇,杜圆圆.rt-PA静脉溶栓治疗急性脑梗死患者的疗效及安全性分析[J].医学综述,2020,26(7):1448-1451,1456.
[4] 董京.急性脑梗死患者阿替普酶静脉溶栓的临床疗效及安全性分析[J].中国药物与临床,2021,21(9):1512-1514.
[5] 张进巧,张辉锋,翟佳佳.静脉溶栓治疗高龄急性脑梗死患者的临床疗效及安全性观察[J].贵州医药,2020,44(8):1226-1227.
[6] 肖淑英, 童燕娜, 孟繁花,等. 老年急性脑梗死患者静脉溶栓治疗临床预后的影响因素分析[J]. 中华老年心脑血管病杂志, 2018, 20(6):4.
[7] 吴晓, 徐冬娟, 李鸿飞,等. rt-PA静脉溶栓治疗高龄急性脑梗死患者的临床观察[J]. 中国药房, 2015, 26(32):3.
[8] 钟文山, 罗崇彬. 1例超高龄急性脑梗死患者静脉溶栓治疗药学监护分析[J]. 中国药业, 2016, 25(20):3.
[9] 农媛, 肖海, 陈奎,等. 高龄急性脑梗死患者尿激酶联合奥扎格雷钠静脉溶栓治疗分析[J]. 吉林医学, 2017, 38(4):4.
[10] 陈宝辉. 醒脑静联合阿加曲班在老年急性脑梗死静脉溶栓治疗中的应用[J]. 河南医学研究, 2021, 30(8):3.
[11] 张福鼎. 尿激酶静脉溶栓治疗70岁以上高龄急性脑梗死患者的疗效分析[J]. 中国冶金工业医学杂志, 2020, 37(6):2.
[12] 杨雯, 傅亚明, 张美霞,等. 高龄急性脑梗死静脉溶栓治疗的有效性和安全性分析[J]. 浙江医学, 2019, 041(009):907-911.
[13] 杨雯, 程兴, 胡传琛,等. 高龄急性脑梗死静脉溶栓治疗的有效性和安全性分析[J]. 浙江医学, 2019, 41(9):5.
[14] 包黎刚. 高龄急性脑梗死患者rt-PA静脉溶栓治疗的有效性研究[J]. 大家健康(中旬版) 2014年12期, 23-23页, 2015.
[15] 崔雪梅. 静脉溶栓治疗老年急性脑梗120例护理体会[J]. 实用临床医药杂志, 2016, 20(2):4.
[16] 严洪新, 罗建华, 余练. 静脉溶栓联合血管内介入治疗中重症急性脑梗死患者预后的影响因素分析[J]. 临床医学工程, 2018, 25(4):2.